12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EP-101: Phase IIb data

The double-blind, crossover, U.S. and U.K. Phase IIb GOLDEN-1 trial in 140 patients with moderate to severe COPD showed that all doses of once-daily EP-101 for 7 days met the co-primary endpoints of improving mean trough FEV1 at 24 hours post-dose (p<0.0005) and 24-hour FEV1 AUC on day 7 vs. placebo (p<0.0001). EP-101 was well tolerated with a...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >